Clinical Trials Logo

Stage IV Lung Adenocarcinoma clinical trials

View clinical trials related to Stage IV Lung Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02120807 Completed - Clinical trials for Stage IV Lung Adenocarcinoma

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Start date: April 15, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer. The investigators want to find out what effects, good and/or bad, certolizumab has on the patient and lung cancer.

NCT ID: NCT00946712 Terminated - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Start date: July 15, 2009
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may prevent the growth of new blood vessels that tumor needs to grow. Cetuximab may also stop cancer cells from growing by binding and interfering with a protein on the surface of the tumor cell that is needed for tumor growth. It is not yet known whether giving carboplatin and paclitaxel are more effective with or without bevacizumab and/or cetuximab in treating patients with non-small cell lung cancer.